Skip to main content

Table 2 Relationship between tumor markers and clinicopathological features

From: NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma

 

cNHERF1

nNHERF1

mNHERF1

cVEGF

 

Negative

Positive

p-value

Negative

Positive

p-value

Negative

Positive

p-value

Negative

Positive

p-value

Characteristics

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

Age

 ≤ 49 years

38

(52.1)

40

(52.6)

0.944

63

(52.9)

15

(50.0)

0.773

70

(53.4)

10

(50.0)

0.774

27

(39.1)

50

(61.7)

0.006

 >  49 years

35

(47.9)

36

(47.4)

56

(47.1)

15

(50.0)

61

(46.6)

10

(50.0)

42

(60.9)

31

(38.3)

Histological type

 IDC

66

(90.4)

72

(94.7)

0.511

111

(93.3)

27

(90.0)

0.820

125

(95.4)

15

(75.0)

0.002

59

(85.5)

78

(96.3)

0.051

 ILC

3

(4.1)

1

(1.3)

3

(2.5)

1

(3.3)

3

(2.3)

1

(5.0)

4

(5.8)

2

(2.5)

 Other

4

(5.5)

3

(3.9)

5

(4.2)

2

(6.7)

3

(2.3)

4

(20.0)

6

(8.7)

1

(1.2)

Tumor size (cm)

  ≤ 2 cm

37

(51.4)

25

(32.9)

0.023

44

(37.0)

18

(62.1)

0.014

50

(38.2)

12

(63.2)

0.039

33

(47.8)

28

(35.0)

0.112

  > 2 cm

35

(48.6)

51

(67.1)

75

(63.0)

11

(37.9)

81

(61.8)

7

(36.8)

36

(52.2)

52

(65.0)

Lymph node status

 Negative

24

(34.3)

30

(41.7)

0.365

42

(36.8)

12

(42.9)

0.557

42

(33.6)

12

(63.2)

0.013

33

(51.6)

24

(30.4)

0.010

 Positive

46

(65.7)

42

(58.3)

72

(63.2)

16

(57.1)

83

(66.4)

7

(36.8)

33

(48.4)

55

(69.6)

Histological grade

 G1

15

(20.5)

11

(14.5)

0.086

17

(14.3)

9

(30.0)

0.077

20

(15.3)

6

(30.0)

0.138

17

(24.6)

7

(8.6)

0.020

 G2

38

(52.1)

31

(40.8)

55

(46.2)

14

(46.7)

60

(45.8)

10

(50.0)

30

(43.5)

37

(45.7)

 G3

20

(27.4)

34

(44.7)

47

(39.5)

7

(23.3)

51

(38.9)

4

(20.0)

22

(31.9)

37

(45.7)

Receptor status

 ER-negative (≤ 10%)

20

(27.4)

23

(30.3)

0.700

38

(31.9)

5

(16.7)

0.099

39

(29.8)

4

(20.0)

0.367

13

(18.8)

32

(39.5)

0.006

 ER-positive (> 10%)

53

(72.6)

53

(69.7)

81

(68.1)

25

(83.3)

92

(70.2)

16

(80.0)

56

(81.2)

49

(60.5)

 PgR-negative (≤ 10%)

24

(32.9)

39

(51.3)

0.023

55

(46.2)

8

(26.7)

0.053

59

(45.0)

4

(20.0)

0.034

27

(39.1)

38

(46.9)

0.338

 PgR-positive (> 10%)

49

(67.1)

37

(48.7)

64

(53.8)

22

(73.3)

72

(55.0)

16

(80.0)

42

(60.9)

43

(53.1)

MIB1

 Negative (≤ 20%)

36

(49.3)

24

(31.6)

0.027

39

(32.8)

21

(70.0)

< 0.001

49

(37.4)

13

(65.0)

0.019

40

(58.0)

23

(28.4)

< 0.001

 Positive (>  20%)

37

(50.7)

52

(68.4)

80

(67.2)

9

(30.0)

82

(62.6)

7

(35.0)

29

(42.0)

58

(71.6)

HER2/neu

 Negative (0, 1+)

43

(65.2)

27

(38.0)

0.002

51

(81.4)

19

(65.5)

0.080

60

(49.2)

10

(58.8)

0.456

38

(63.3)

30

(39.5)

0.006

 Positive (3+)

23

(34.8)

44

(62.0)

57

(18.6)

10

(34.5)

62

(50.8)

7

(41.2)

22

(36.7)

46

(60.5)

 

cVEGFR1

MVD

nH1F-1α

nTWIST1

 

Negative

Positive

p-value

Negative

Positive

p-value

Negative

Positive

p-value

Negative

Positive

p-value

Characteristics

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

Patient age

  ≤ 49 years

43

(53.1)

41

(51.2)

0.816

35

(48.6)

43

(50.6)

0.805

50

(51.5)

30

(53.6)

0.809

36

(52.9)

35

(48.6)

0.609

  > 49 years

38

(46.9)

39

(48.8)

37

(51.4)

42

(49.4)

47

(48.5)

26

(46.4)

32

(47.1)

37

(51.4)

Histological type

 IDC

71

(87.7)

77

(96.2)

0.041

68

(94.4)

76

(89.4)

0.514

91

(93.8)

50

(89.3)

0.502

63

(92.6)

66

(91.7)

0.663

 ILC

6

(7.4)

0

(0.0)

2

(2.8)

4

(4.7)

2

(2.1)

3

(5.4)

3

(4.4)

2

(2.8)

 Other

4

(4.9)

3

(3.8)

2

(2.8)

5

(5.9)

4

(4.1)

3

(5.4)

2

(2.9)

4

(5.6)

Tumor size (cm)

  ≤ 2 cm

39

(48.8)

29

(36.2)

0.110

36

(50.0)

31

(36.9)

0.100

36

(37.1)

29

(52.7)

0.062

26

(38.8)

32

(44.4)

0.501

  > 2 cm

41

(51.2)

51

(63.8)

36

(50.0)

53

(63.1)

61

(62.9)

26

(47.3)

41

(61.2)

40

(55.6)

Lymph node status

 Negative

33

(44.0)

27

(35.1)

0.260

26

(38.2)

32

(39.5)

0.874

31

(34.4)

26

(47.3)

0.125

25

(39.1)

27

(39.7)

0.940

 Positive

42

(56.0)

50

(64.9)

42

(61.8)

49

(60.5)

59

(65.6)

29

(52.7)

39

(60.9)

41

(60.3)

Histological grade

 G1

14

(17.3)

11

(13.8)

0.246

12

(16.7)

15

(17.6)

0.898

13

(13.4)

12

(21.4)

0.001

10

(14.7)

14

(19.4)

0.251

 G2

40

(49.4)

32

(40.0)

32

(44.4)

40

(47.1)

34

(35.1)

32

(57.1)

26

(38.2)

34

(47.2)

 G3

27

(33.3)

37

(46.2)

28

(38.9)

30

(35.3)

50

(51.5)

12

(21.4)

32

(47.1)

24

(33.3)

Receptor status

 ER-negative (≤ 10%)

21

(25.9)

29

(36.2)

0.157

19

(26.4)

26

(30.6)

0.562

32

(33.0)

16

(28.6)

0.570

24

(35.3)

15

(20.8)

0.056

 ER-positive (> 10%)

60

(74.1)

51

(63.8)

53

(73.6)

59

(69.4)

65

(67.0)

40

(71.4)

44

(64.7)

57

(79.2)

 PgR-negative (≤ 10%)

26

(32.1)

42

(52.3)

0.009

32

(44.4)

33

(38.8)

0.476

48

(49.5)

18

(32.1)

0.037

34

(50.0)

30

(41.7)

0.323

 PgR-positive (> 10%)

55

(67.9)

38

(47.5)

40

(55.6)

52

(61.2)

49

(50.5)

38

(67.9)

34

(50.0)

42

(58.3)

MIB1

 Negative (≤ 20%)

37

(45.7)

29

(36.2)

0.224

32

(44.0)

34

(40.0)

0.574

31

(32.0)

29

(51.8)

0.016

22

(32.4)

38

(52.8)

0.015

 Positive (>  20%)

44

(54.3)

51

(63.8)

40

(55.6)

51

(60.0)

66

(68.0)

27

(48.2)

46

(67.6)

34

(47.2)

HER2/neu

 Negative (0, 1+)

41

(58.6)

34

(44.7)

0.095

34

(54.0)

36

(48.0)

0.485

40

(44.9)

32

(61.5)

0.057

29

(46.8)

35

(50.7)

0.652

 Positive (3+)

29

(41.4)

7

(55.3)

29

(46.0)

39

(52.0)

49

(55.1)

20

(38.5)

33

(53.2)

34

(49.3)

  1. p-value of Chi-squared test for the independence of categorical variables. Bold values indicate significance
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us